Supplemental New Drug Application for at-home Igalmi aims to provide a self-administered option for agitation in schizophrenia and bipolar disorder.
ZYCUBOapproved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 mi ...
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that the U.S. Food ...
India, March 30 -- A viral video showing a delivery agent standing motionless and unresponsive for nearly two hours has sparked widespread concern and speculation about possible health or ...
Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR) - An Endemic Aero-Allergic Disease in India Allergic ...
In a study published in Neuron, Ciaran Murphy-Royal, researcher at the Center de recherche du Center hospitalier de ...
NDA submitted seeking approval of IGALMI in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports ...
Morning Overview on MSN
Study links common blood pressure drug to improved cancer immunotherapy
Researchers have found that amlodipine, a calcium-channel blocker prescribed to tens of millions of people for high blood ...
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease ...
Bausch + Lomb (NYSE:BLCO) highlighted two glaucoma programs during a Wells Fargo-hosted “2026 MedTech Innovation Spotlight” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results